Positive Health Online
Your Country
Research: PATZELT-WENCZLER and P
Listed in Issue 57
Abstract
PATZELT-WENCZLER and PONCE-POSCHL, ASTA Medica AG, Weismullerstr. 45, D-60314 Frankfurt am Main, Germany. Dr_Jeannette.Simon@astamedica.de conducted a trial into the efficacy of Kamillosan® cream in atopic eczema.
Background
Kamillosan® cream contains chamomile extract as an active principle manufactured from the chamomile sort Manzana and has been proved not to exhibit a chamomile-related allergen potential. For this reason Kamillosan® cream is suited for local therapy of atopic eczema.
Methodology
In a partially double-blind, randomized study carried out as a half-side comparison, Kamillosan® cream was tested vs. 0.5% hydrocortisone cream and the vehicle cream as placebo in patients suffering from medium-degree atopic eczema.
Results
After a two-week treatment Kamillosan® cream showed a mild superiority towards 0.5% hydrocortisone and a marginal difference as compared to placebo.
Conclusion
References
Patzelt-Wenczler R and Ponce-Poschl E. Proof of efficacy of Kamillosan® cream in atopic eczema. European Journal of Medical Research 5(4): 171-5. Apr 2000.
Comment
There is a large amount of anecdotal writings on the use of chamomile for skin conditions such as eczema so it is good news to see a clinical trial showing that it may be comparable to a hydrocortisone cream.